Recruiting

Anticoagulation

Sponsor:

Mayo Clinic

Code:

NCT03504007

Conditions

Acute Deep Vein Thrombosis

Acute Pulmonary Embolism

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The Gonda Vascular Center- Thrombophilia Clinic at Mayo Clinic in Rochester, Minnesota utilizes a standardized, guideline-directed, yet patient-oriented approach for treating patients diagnosed with venous thromboembolism (VTE).This study is the ongoing registry of clinical practice with standardized approach to patient assessment and therapy. As most of registries it does not have any definite number of recruited subjects or the date of study completion but provides anticipated number of recruited subjects and the time of anticipated enrolment which was provided only because of formal requirement related to structure of ClinicalTrials.gov website. This number will be updated and upgraded as we continue this registry.

The rates of VTE recurrence, major bleeding, clinically relevant non-major bleeding (CRNMB) and survival in patients treated with anticoagulation for acute VTE are assessed during prospective observation. VTE cases include an acute deep vein thrombosis (DVT) of lower or upper extremities, splanchnic veins, gonadal, renal, cerebral veins thrombosis and pulmonary embolism (PE). Therapy includes the whole spectrum of FDA approved anticoagulants such as "classic" agents: warfarin and heparinoids and the newer direct oral anticoagulants (DOACs) such as rivaroxaban, dabigatran, apixaban, and edoxaban.

Conditions

Acute Deep Vein Thrombosis

Acute Pulmonary Embolism

Study ID

NCT03504007

Start date

Mar 1, 2013

Status verified date

Apr, 2026

Completion date

Mar, 2033

Anticipated

Primary completion date

Mar, 2033

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

• VTE seen at Thrombophilia Clinic and treatment with anti-coagulant is started within 14 days of VTE diagnosis date.

Exclusion Criteria:

  • Patients already on anticoagulation for other reasons or enrolled into anticoagulation clinical trials.

Study Design

Enrollment

10000 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Incidence of symptomatic, recurrent VTE. Incidence of major bleeding [ Time Frame: 10 years ]

Central Contacts and Locations

Central contacts

Damon Houghton, MD, MS

507-266-6717vteregistry@mayo.edu

Danielle Vlazny, P.A.-C., M.S.

507-266-6717vteregistry@mayo.edu

Locations

Mayo Clinic

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Principal Investigator:

Damon Houghton, MD, MS

More Information

Sponsor

Mayo Clinic

Last update posted

Apr 27, 2026

Last verified

Apr, 2026

Keywords

  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Apixaban
  • Rivaroxaban
  • Dabigatran
  • Edoxaban

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-04-27.